about
A new class of vitamin D analogues that induce structural rearrangement of the ligand-binding pocket of the receptorStromal cell-derived factor 1-mediated CXCR4 signaling in rat and human cortical neural progenitor cellsCXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cellsIdentification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries.Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides.Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds.Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities.Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening.Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore.Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids.Synthesis of protein kinase Cdelta C1b domain by native chemical ligation methodology and characterization of its folding and ligand binding.Peptide HIV-1 integrase inhibitors from HIV-1 gene products.Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.Fluorescence-quenching screening of protein kinase C ligands with an environmentally sensitive fluorophore.Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.[Development of anti-HIV agents based on chemical biology].Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.Pharmacophore-based small molecule CXCR4 ligands.Low-molecular-weight CXCR4 ligands with variable spacers.Fluorescent-responsive synthetic C1b domains of protein kinase Cδ as reporters of specific high-affinity ligand bindingThe therapeutic potential of CXCR4 antagonists in the treatment of HIV.Retrograde migration of pectoral girdle muscle precursors depends on CXCR4/SDF-1 signaling.Screening for protein kinase C ligands using fluorescence resonance energy transfer.Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists.Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.Development of anti-HIV peptides based on a viral capsid protein.Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.The chemokine receptor CXCR4 as a therapeutic target for several diseases.Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsExploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury.Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.The successes and failures of HIV drug discovery.A future perspective on the development of chemokine receptor CXCR4 antagonists.Peptide-based ligand screening and functional analysis of protein kinase C.Multimerized HIV-gp41-derived peptides as fusion inhibitors and vaccines.
P50
Q27653647-6D988D9C-5142-4A4A-8E26-864B91F9812AQ28576470-015F37DD-0E2D-41E6-8D99-A0F36DF49632Q30480094-C4C56302-C463-4B78-8045-8CABE0F7B857Q31164451-9976AEC0-507A-4324-9946-73FDA34426D0Q33187844-DD76281A-06A3-44C3-BF25-15248F28161EQ33200970-C2244C33-61A0-4C00-8C40-D37752DB7F6AQ33228479-A247D245-D101-4C37-87E3-36925AD38A65Q33269471-0D0EF6F7-856B-4F9F-8D84-3D398540556EQ33271153-F95DB19B-D58F-47AF-9C53-A24B964B278EQ33360574-CE6DE917-A90B-47B9-B2F6-A29FD02F7931Q33384138-F914011E-FDB5-433D-9770-D110A2BAD1A2Q33496804-867A0BD3-6C88-4B6F-AD77-64722969EC72Q33610576-8593908E-B5E5-4D23-AA55-E992023B560EQ33619612-5A5A32EB-6ABE-4BCB-A91D-3A1AD4E0A72EQ33657660-FE270DB3-D144-405F-9DB6-62B26CCCF4CDQ33854664-E9444341-A1C2-4B2F-B4E5-AC9FC53CF85FQ33964006-D482F30B-5B70-43E2-8AE9-B47BD302AAA2Q34116407-3794C328-12B2-41D6-AFDD-BBEEAFA564C1Q34141110-7A3E5E9A-3FE3-4A1C-9068-59B7829B4BC3Q34266703-B11EA10C-97D0-4BB2-9851-E3C76E3EA58CQ34453685-29CF376D-4C16-4C1D-A739-EB8277F8EABDQ34792902-AD2E6472-46A0-4966-B706-1F2C7F098EAAQ35056053-4826F484-726A-4577-A4FA-EF051CE5C874Q35196669-01A0FF83-DF8E-48E1-89E5-3A479B641C2FQ35222542-FE185622-F8C0-49AA-BB8D-FBC6731F4D20Q35793790-302A1D50-A474-41C1-B7BC-AD71993E5FDAQ35927570-DDC6F9DB-AA95-43B2-9DC7-E31358EA4C01Q36080284-6F2DCEF8-1F7C-4D18-B47B-347E31EBC285Q36297767-2162A47F-8835-40B5-98AC-62EEFE4D1E06Q36318564-6BE55877-50F4-4827-97CC-CE76470CABA3Q36612235-99BB2B19-2ED2-4B00-A977-B2D38442ADA0Q36682750-5783A00A-0D7F-4AB0-A53E-0BD5013EAA49Q36703042-21541509-7CBD-41DB-832F-E4ACA3BBEFDBQ37352728-E6812924-3592-420D-A1F0-7956AB1BAF6DQ37728238-D7C2559D-408E-483A-A55E-FD0DCCD64947Q37742855-26ABB493-5CF6-49DF-BFE4-58B26FC978B7Q38014557-F1C07E10-8CF2-4565-97A9-F477163A15A2Q38089173-5BFE21C3-C357-4232-91E0-B3A32695896EQ38125116-483278BE-2F14-47C9-9FA0-F80B0BE50ABDQ38638340-F99725F0-99A4-4386-AC9C-09F06E5E6127
P50
description
Japanese pharmacologist
@en
日本の薬学者
@ja
name
Hirokazu Tamamura
@en
玉村啓和
@ja
다마무라 히로카즈
@ko
type
label
Hirokazu Tamamura
@en
玉村啓和
@ja
다마무라 히로카즈
@ko
altLabel
Tamamura Hirokazu
@en
prefLabel
Hirokazu Tamamura
@en
玉村啓和
@ja
다마무라 히로카즈
@ko
P106
P1412
P1559
玉村 啓和
@ja